Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy NGM Biopharmaceuticals stock

Learn how to easily invest in NGM Biopharmaceuticals stock.

NGM Biopharmaceuticals Inc is a biotechnology business based in the US. NGM Biopharmaceuticals shares (NGM) are listed on the NASDAQ and all prices are listed in US Dollars. NGM Biopharmaceuticals employs 225 staff and has a trailing 12-month revenue of around $68.8 million.

How to buy shares in NGM Biopharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NGM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

NGM Biopharmaceuticals stock price (NASDAQ: NGM)

Use our graph to track the performance of NGM stocks over time.

NGM Biopharmaceuticals shares at a glance

Information last updated 2022-09-18.
Latest market close$12.59
52-week range$10.49 - $23.25
50-day moving average $15.62
200-day moving average $15.30
Wall St. target price$32.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.61

Buy NGM Biopharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NGM Biopharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NGM Biopharmaceuticals price performance over time

Historical closes compared with the close of $12.59 from 2022-09-23

1 week (2022-09-16) -16.07%
1 month (2022-08-25) -20.16%
3 months (2022-06-24) -14.24%
6 months (2022-03-25) -20.87%
1 year (2021-09-24) -43.44%
2 years (2020-09-25) -23.23%
3 years (2019-09-25) 15.75
5 years (2017-09-21) N/A

NGM Biopharmaceuticals financials

Revenue TTM $68.8 million
Gross profit TTM $-83,830,000
Return on assets TTM -22.34%
Return on equity TTM -40.61%
Profit margin -196.39%
Book value $3.68
Market capitalisation $1.2 billion

TTM: trailing 12 months

NGM Biopharmaceuticals share dividends

We're not expecting NGM Biopharmaceuticals to pay a dividend over the next 12 months.

NGM Biopharmaceuticals share price volatility

Over the last 12 months, NGM Biopharmaceuticals's shares have ranged in value from as little as $10.49 up to $23.25. A popular way to gauge a stock's volatility is its "beta".

NGM.US volatility(beta: 1.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NGM Biopharmaceuticals's is 1.672. This would suggest that NGM Biopharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

NGM Biopharmaceuticals overview

NGM Biopharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. ; and a collaboration agreement with Merck & Co. , Inc.

Frequently asked questions

What percentage of NGM Biopharmaceuticals is owned by insiders or institutions?
Currently 21.295% of NGM Biopharmaceuticals shares are held by insiders and 63.864% by institutions.
How many people work for NGM Biopharmaceuticals?
Latest data suggests 225 work at NGM Biopharmaceuticals.
When does the fiscal year end for NGM Biopharmaceuticals?
NGM Biopharmaceuticals's fiscal year ends in December.
Where is NGM Biopharmaceuticals based?
NGM Biopharmaceuticals's address is: 333 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
What is NGM Biopharmaceuticals's ISIN number?
NGM Biopharmaceuticals's international securities identification number is: US62921N1054
What is NGM Biopharmaceuticals's CUSIP number?
NGM Biopharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 62921N105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site